Using national data to model the New Zealand radiation oncology workforce.

Health Workforce Health Workforce Modelling Health Workforce Supply and Demand Planning radiation oncology radiotherapy/radiation therapy

Journal

Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 03 02 2022
accepted: 03 06 2022
pubmed: 1 7 2022
medline: 6 8 2022
entrez: 30 6 2022
Statut: ppublish

Résumé

Demand for radiation therapy is expected to increase over time. In Aotearoa/New Zealand, the radiation oncology workforce experiences high numbers of clinical hours but an intervention rate that is lower than in comparable countries, suggesting unmet treatment need. Accurate models on the supply and demand for radiation oncologists (ROs) are needed to ensure adequate staffing levels. We developed a demand model that predicted the future number of ROs required, using national data from the Radiation Oncology Collection (ROC) and a survey of ROs. Radiation therapy intervention and retreatment rates (IR/RTRs), and benign and non-cancer conditions being treated, were derived from the ROC and applied to Census population projections. Survey data provided definitions of treatment by complexity, time spent in different activities and time available for work. Results were linked to radiation oncology workforce forecasts from a supply model developed by the Ministry of Health. The demand model showed that 85 ROs would be needed in 2031, if current IR/RTRs were maintained, an increase from 68 in 2021. The supply model predicted a decrease in ROs over time, leaving a significant shortfall. Model parameters could be modified to assess the impact of workforce or practice changes; more ROs would be needed if average working hours reduced or IR/RTRs increased. Workforce models based on robust data collections are an important tool for workforce planning. The RO demand model presented here combines detailed information on treatment and work activities to provide credible estimates that can be used to inform actions on training, recruitment and retention.

Identifiants

pubmed: 35768935
doi: 10.1111/1754-9485.13448
pmc: PMC9542613
doi:

Substances chimiques

Reactive Oxygen Species 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

708-716

Subventions

Organisme : Te Aho o Te Kahu - Cancer Control Agency

Informations de copyright

© 2022 The Authors. Journal of Medical Imaging and Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Radiologists.

Références

Radiother Oncol. 2018 Feb;126(2):183-190
pubmed: 28988660
Eur J Cancer Care (Engl). 2018 Mar;27(2):e12804
pubmed: 29341295
N Z Med J. 2015 Apr 17;128(1412):39-46
pubmed: 25899491
Strahlenther Onkol. 2016 Sep;192(9):599-608
pubmed: 27457976
Asia Pac J Clin Oncol. 2011 Mar;7(1):56-64
pubmed: 21332652
JAMA Oncol. 2018 Jan 11;4(1):e173501
pubmed: 28973074
Eur J Cancer. 2014 Oct;50(15):2735-43
pubmed: 25085229
Clin Transl Oncol. 2019 Dec;21(12):1663-1672
pubmed: 30941701
Radiother Oncol. 2014 Aug;112(2):165-77
pubmed: 25245560
N Z Med J. 2019 Nov 8;132(1506):52-59
pubmed: 31778372
J Med Imaging Radiat Oncol. 2015 Feb;59(1):115-24
pubmed: 25088562
Hematol Oncol Clin North Am. 2019 Dec;33(6):1095-1104
pubmed: 31668208
J Med Imaging Radiat Sci. 2019 Jun;50(2):243-251
pubmed: 31176432
J Med Imaging Radiat Oncol. 2012 Dec;56(6):708-9
pubmed: 23210593
J Med Imaging Radiat Oncol. 2014 Feb;58(1):125-33
pubmed: 24118771
Eur J Cancer Care (Engl). 2014 Jan;23(1):82-8
pubmed: 23844995
J Med Imaging Radiat Oncol. 2018 Oct;62(5):684-691
pubmed: 29718574
J Med Radiat Sci. 2018 Jun;65(2):86-96
pubmed: 29864246
J Allied Health. 2014 Summer;43(2):110-6
pubmed: 24925038
J Med Imaging Radiat Sci. 2015 Dec;46(4):388-395
pubmed: 31052119
Eur J Oncol Nurs. 2016 Apr;21:134-8
pubmed: 26456901
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
Radiother Oncol. 2014 Aug;112(2):178-86
pubmed: 25300718
Radiother Oncol. 2014 Jul;112(1):140-4
pubmed: 24833561
Clin Oncol (R Coll Radiol). 2011 Feb;23(1):4-9
pubmed: 21055912
J Med Imaging Radiat Oncol. 2017 Feb;61(1):146-155
pubmed: 27797163
N Z Med J. 2020 Dec 18;133(1527):15-25
pubmed: 33332325
J Clin Oncol. 2020 Sep 1;38(25):2830-2838
pubmed: 32484754

Auteurs

Alex Dunn (A)

Te Aho o Te Kahu/Cancer Control Agency, Wellington, New Zealand.

Shaun Costello (S)

Southern District Health Board, Dunedin, New Zealand.

Fiona Imlach (F)

Te Aho o Te Kahu/Cancer Control Agency, Wellington, New Zealand.

Emmanuel Jo (E)

Health Workforce Directorate, Ministry of Health, Wellington, New Zealand.
Department of Medicine, School of Medicine, University of Auckland, Auckland, New Zealand.

Jason Gurney (J)

Te Aho o Te Kahu/Cancer Control Agency, Wellington, New Zealand.
Cancer and Chronic Conditions (C3) Research Group, Department of Public Health, University of Otago, Wellington, New Zealand.

Rose Simpson (R)

Te Aho o Te Kahu/Cancer Control Agency, Wellington, New Zealand.

Diana Sarfati (D)

Te Aho o Te Kahu/Cancer Control Agency, Wellington, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH